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Ceramide is a building block for complex sphingolipids in the plasma membrane, but it also plays a significant role in secondary
signalling pathways regulating cell proliferation and apoptosis in response to stress. Ceramide activated protein phosphatase activity
has been previously observed in association with the Sit4 protein phosphatase. Here we find that sit4Δ mutants have decreased
ceramide levels and display resistance to exogenous ceramides and phytosphingosine. Mutants lacking SIT4 orKTI12 display a shift
towards nonhydroxylated forms of long chain bases and sphingolipids, suggesting regulation of hydroxylase (SUR2) or ceramide
synthase by Sit4p.We have identified novel subunits of the Sit4 complex and have also shown that known Sit4 regulatory subunits—
SAP proteins—are not involved in the ceramide response. This is the first observation of separation of function between Sit4 and
SAP proteins.We also find that the Sit4p target Elongator is not involved in the ceramide response but that cells deficient in Kti12p—
an accessory protein with an undefined regulatory role—have similar ceramide phenotypes to sit4Δmutants.Therefore, Kti12pmay
play a similar secondary role in the ceramide response. This evidence points to a novel Sit4-dependent regulatory mechanism in
response to ceramide stress.
1. Introduction
Ceramide is a building block for complex sphingolipids
which comprise an important structural component of the
plasma membrane. It is also a secondary signalling molecule
that accumulates in response to stresses such as heat shock
[1]. It is therefore important for sphingolipid metabolism
to be tightly regulated, and the damaging effects of dys-
regulation are apparent in patients with Tay-Sachs disease,
Fabry disease, and other inherited sphingolipidosis disorders
[2]. Ceramide mediates controlled cell death by triggering
several signalling cascades to initiate caspase-dependent and
independent apoptosis [3]. In contrast, the phosphorylated
ceramide precursors dihydrosphingosine (DHSP) and phy-
tosphingosine (PHSP) are signals for pathways that promote
cell proliferation [4].
Although it is known that the cellular response to
ceramide is important for the regulation of cell proliferation
and cell death pathways, the precise molecular mechanisms
for this regulation still remain elusive. It is vital to further
understand the way cells respond to stress in order to develop
strategies tomodify them, either to accelerate cell death using
targeted anticancer drugs or to prevent accumulation of toxic
products in sphingolipidoses [5–7].
Saccharomyces cerevisiae has been used effectively as a
model to study sphingolipid metabolism, and Figure 1 shows
a detailed summary of the sphingolipid biosynthetic pathway
in yeast [8]. Many of the genes involved are conserved from
yeast to higher eukaryotes, with diversion in the synthesis of
complex sphingolipids occurring only after the production of
ceramides, resulting in the production of different end prod-
ucts in the pathway. The addition of inositol to ceramide in
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Figure 1: Biosynthesis of sphingolipids in Saccharomyces cerevisiae. Key enzymes discussed in the text are highlighted and genes encoding
all relevant parts of the pathway are included. The directions of arrows indicate the end products of enzymatic reactions.
yeast forms inositol phosphoceramide, and glucose, galactose
or phosphorylcholine is added to ceramide in mammalian
cells to generate glycosphingolipids and sphingomyelin
[9].
Early work by Nickels and Broach showed that a cera-
mide-activated phosphatase activity was present in Saccha-
romyces cerevisiae, which is separate from the activity of
the major PP2A phosphatases Pph21p and Pph22p [10]. The
ceramide resistance of a sit4Δmutant strain suggested that the
PP2A-like phosphatase Sit4p is responsible for this activity.
SIT4 is an essential gene in the absence of the suppressor
allele SSD1-v and has important roles in the progression of
the cell cycle, cell integrity, nutrient responses via TORC1,
drug resistance via efflux pumps, and tRNA modification
[11–16]. Diverse regulatory subunits of Sit4p are partially
responsible for the different specificities of Sit4p; for exam-
ple, Tap42p is phosphorylated by Tor and binds Sit4p [17]
and Sap185p and Sap190p subunits are essential for correct
phosphoregulation of Elongator and tRNAmodification [18].
Mutation of the SAPs (Sit4 associated proteins) can confer
different specificities on Sit4p but a deletion of all four SAPs
always results in the same phenotypes as deletion of SIT4, for
example resistance to the tRNAse toxin zymocin, cell cycle
arrest, and sensitivity to rapamycin [19, 20]. The accessory
protein Kti12p is also essential for the phosphoregulation of
the Elongator subunit Elp1p by the Sit4p/Sap185p/Sap190p
complex. Kti12p interacts with the casein kinase Hrr25p
in an Elongator-dependent manner but the mechanism by
which Kti12p regulates phosphorylation remains unclear
[21].
The aim of this study was to further investigate the
role of Sit4 as the ceramide-activated protein phosphatase
(CAPP) in yeast. We identify KTI12 as an important gene
mediating ceramide toxicity and show that ceramide toxicity
is independent of Elongator function. Mutants lacking SIT4
orKTI12 have decreased levels of ceramide and the balance of
hydroxylated and nonhydroxylated sphingolipids is altered.
The confirmation that Tpd3p and Cdc55p can interact with
Sit4p and a separation of function between SIT4 and the reg-
ulatory SAP subunits indicates that the CAPP is likely to be
an alternative Sit4 complex operating via a novel mechanism.
2. Methods
2.1. Yeast Strains and Media. Yeast were routinely grown
in yeast extract peptone dextrose medium (YPD; 1% yeast
extract, 1% peptone, 2% glucose) at 30∘C with shaking.
Glucose was replaced with 2% galactose to induce expression
of SIT4 and PPH21 from the GAL1 promoter. Synthetic
defined medium without inositol (0.67% yeast nitrogen base,
2% glucose, supplemented with essential amino acids) was
used for labelling with [ 3H]myo-inositol. Yeast strains used
in this study are listed in Table 1.
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Table 1: Yeast strains used in this study.
Strain Genotype Reference
CY4029 Mat a ade2-1 his3-11,15 leu2-3,112 trp1-1 ura3-1 can1-100 SSD1-v1 gal+ [20]
CY3938 CY4029, sit4Δ::HIS3 [20]
CY5236 CY4029, sap4Δ::LEU2 sap155Δ::HIS3 sap185Δ::ADE2 sap190Δ::TRP1 [20]
CY5220 CY4029, sap4Δ::LEU2 sap155Δ::HIS3 [20]
CY5224 CY4029, sap185Δ::ADE2 sap190Δ::TRP1 [20]
CY4917 CY4029, sap185Δ::ADE2 [20]
CY4380 CY4029, sap190Δ::TRP1 [20]
DJY101 CY4029, sit4Δ::HIS3 kti12ΔKlLEU2 [18]
LFY3 Mat a ade2-1 his3-11,15 leu2-3,112, ura3-1 can1-100, elp1Δ::TRP1 [18]
LFY4 Mat a ade2-1 his3-11,15 leu2-3,112, ura3-1 can1-100, elp2Δ::TRP1 [18]
LFY5 Mat a ade2-1 his3-11,15 leu2-3,112, ura3-1 can1-100, elp3Δ::TRP1 [22]
LFY6 Mat a ade2-1 his3-11,15 leu2-3,112, ura3-1 can1-100, kti12Δ::TRP1 [22]
AWY1 CY4029 TRP1::GAL1::(HA)3-SIT4 CDC55-(c-myc)3::HIS3MX6 This study
AWY2 CY4029, kanMX6::PGAL1::(HA)3-PPH21, CDC55-(c-myc)3::HIS3MX6 This study
AWY3 CY4029, CDC55-(c-myc)3::HIS3MX6 This study
2.2. Growth Tests Using Ceramide and Long Chain Bases. C2-
ceramide, C2-phytoceramide, dihydrosphingosine (DHS),
and phytosphingosine (PHS) powders were purchased from
Enzo Life Sciences and resuspended in 100% ethanol. Stock
solutions (5mg/mL) were stored at −20∘C for a maximum
of 1 week. Yeast cultures were diluted from a starter culture
to 5 × 103 cells/mL in YPD containing ceramides/long
chain bases or an equal volume of ethanol as an untreated
control. Cultures were grown until the untreated control
reached exponential phase (from 15–36 hours depending
on the strain) and the OD
600
measured for both treated
and untreated cultures. After 24 hours, an additional dose
of ceramide/long chain base was added to counteract the
effects of compound degradation. The amount of growth
in each concentration of ceramide/long chain base was
then expressed as a percentage of the growth in untreated
media. This method of standardising growth enables the
comparison of slow-growingmutants such as sit4Δ to a faster-
growing wild-type strain. Raw OD
600
data is provided in
Supplementary Tables 1 and 2 (see Supplementary Material
available online at http://dx.doi.org/10.1155/2013/129645). A
minimum of three biological replicates were performed for
each strain and a one-way ANOVAwith Bonferroni post-test
was used to determine if growth was significantly different
from the wild type (CY4029).
2.3. Immunoprecipitation. Dynabeads (Invitrogen) were cou-
pledwith 5 𝜇g of anti-HA antibody permg of beads, following
the manufacturer’s instructions. Total protein extracts were
prepared from 50mL cultures grown for 8 hours in YPD
supplemented with galactose. Cell pellets were resuspended
in 400𝜇L B60 buffer (50mMHEPES pH 7.3, 60mM sodium
acetate, 5mM magnesium acetate, 0.1% Triton X-100, 10%
glycerol, 1mM sodium fluoride, 20mM glycerophosphate,
1mM DTT, 1X Complete Mini Protease Inhibitor Cocktail
(Roche)). An equal volume of glass beads was added and
cells disrupted using a bead beater for 1 minute, followed by
centrifugation at 15700 g, 4∘C for 5 minutes. The supernatant
was transferred to a new tube and centrifuged at 15700 g, 4∘C
for 20 minutes. The cleared protein extract was quantified
using spectrophotometry and 3.5mg of total protein extract
was incubated with 1.5mg of antibody-coated beads for 30
minutes at 4∘C. Unbound proteins were removed by three
washes with 1mL B60 buffer, and antibody-bound proteins
were eluted with 50 𝜇L of 10% (v/v) SDS for 10 minutes at
room temperature. The beads were then removed with a
magnet and the supernatant used for Western blot analysis.
SDS-PAGE of 100𝜇g of total protein from each strain and
immunoprecipitation supernatants (equal volumes) was car-
ried out using 12% acrylamide gels and then Western blotted
at 100V for 1 hour. Blots were probed with anti-HA (F7
Santa Cruz), anti-c-myc (A14 Santa Cruz), or anti-Tpd3 (Y.
Jiang, University of Pittsburg School of Medicine, USA) and
secondary antibodies conjugated to horseradish peroxidase
(Roche Diagnostics) were detected by chemiluminescence
and exposed to X-ray film.
2.4. Sphingolipid Analysis by ESI-MS. Overnight cultures
grown at 24∘C in YPD media were diluted to OD
600
0.2
and grown until they reached OD
600
of 2. A total of 10OD
units of cells were collected and washed once with sterile
water. Lipid extraction was performed by a two-step lipid
extraction method [23]. Cells were resuspended in 1mL of
150mM ammonium bicarbonate (NH
4
HCO
3
) and 600𝜇L
of glass beads were added. After cell lysis using a Precellys
24 homogenizer ((Bertin technologies) 5000 rpm, 3x 30 sec
on 30 sec off), lysates were diluted in 5mL of 150mM
NH
4
HCO
3
solution and internal standards were added.
Long chain bases and ceramides were quantified relative to
respective lipid standards, and inositol phosphoceramides
were measured relative to a phosphoinositol standard. Lipid
standards were purchased from Avanti Polar Lipids. ESI-MS
analysis was performed using a Bruker Esquire HCT ion trap
mass spectrometer in positive or negative ion mode. Peaks
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Figure 2: Deletion of SIT4 orKTI12 confers resistance to excess dihydroceramide. (a) Ceramide growth tests in Sit4 associated protein (SAP)
mutants. (b) Ceramide growth tests in Elongator-associated mutants. Yeast cultures were diluted to 5 × 103 cells/mL in YPDwith the addition
of either 15𝜇MC-2 dihydroceramide or an equal volume of ethanol. Cells were grown until the untreated culture reached exponential phase
and the OD
600
of all cultures was determined. Growth in 15𝜇Mdihydroceramide is expressed as a percentage of untreated growth. RawOD
600
values are given in Supplementary Table 1. A minimum of three replicates are shown and error bars represent the standard deviation above
and below the mean. A one-way ANOVA with a Bonferroni post-test was used to determine if mutants showed a significant difference in
growth compared to the wild type (CY4029) ( ∗∗𝑃 < 0.01, ∗∗∗𝑃 < 0.001, and ∗∗∗∗𝑃 < 0.0001).
were identified based on their fragmentation pattern and
by comparison to commercially available standards. Three
biological replicates were included in each analysis.
2.5. Incorporation of [3H]-Labelled Inositol. Overnight cul-
tures grown at 24∘C in YPD were diluted to OD
600
1.0 in syn-
thetic defined media containing 40 𝜇Ci [ 3H] myo-inositol
(American Radiolabelled Chemicals, MO, USA) and grown
at 24∘C for 4 h until they reachedOD
600
of approximately 2. A
total of 10OD units were harvested, and lipids were extracted
using chloroform/methanol/water (10 : 10 : 3) and analysed
as previously described [24] by thin layer chromatography
with or without mild-base treatment. Mild-base treatment
to remove inositol phosphate and leave only N-acetylated
sphingolipids was performed by incubating lipids in 0.1M
NaOH at 30∘C for 1 hour. Radioactivity was detected using
a phosphorimager (Typhoon FLA9500, GE Healthcare) and
a representative image of two biological replicates is shown.
3. Results
3.1. Deletion of Sit4-Associated Proteins (SAPs) Does Not
Confer Resistance to Exogenous Dihydroceramide. As previ-
ously described [10], deletion of SIT4 leads to significant
resistance to 15𝜇M dihydroceramide (Figure 2, 𝑃 < 0.0001).
However,mutation of the four SAP regulatory proteins, either
individually or in combination, does not confer resistance
to dihydroceramide (Figure 2(a)). In previous studies, the
phenotype of the quadruple sap mutant has been indistin-
guishable from that of sit4Δ [19, 20]. Thus, the ceramide
sensitivity of the sap mutant is the first observed separation
of function between sit4Δ and sapΔΔΔΔ.
3.2. Kti12p Appears to Be the Only Elongator-Associated
Protein Involved in the Ceramide Response. As Sit4p plays a
major role in the phosphoregulation of the Elongator com-
plex [18, 21] and previous studies suggested that Elongator
mutants were resistant to ceramide, Elongator components
were investigated as potential targets of Sit4p in the response
to excess dihydroceramide. Although deletion of Elongator
subunits did not confer statistically significant resistance to
15 𝜇M dihydroceramide, deletion of the Elongator acces-
sory protein Kti12p did confer resistance (Figure 2(b)) to
some extent, though the obtained data were rather variable
(Supplementary Table 1). Interestingly, deletion of SIT4 and
KTI12 in tandem restored sensitivity to dihydroceramide,
whereas in a previous study mutants lacking one or both
of these genes had the same phenotype that resulted in
hyperphosphorylation of Elp1p and zymocin resistance [18].
In addition, phosphorylation of Elp1p was unchanged in the
presence of dihydroceramide, and this was not affected by
deletion of SIT4 and/or KTI12 (data not shown). Therefore,
our data suggest that Kti12p might play a regulatory role in
the ceramide response that is independent of Elongator.
3.3. PHS Resistance of sit4Δ Indicates Separation of Func-
tion from kti12Δ. Growth in phytoceramide decreases in
a concentration-dependent manner in both wild-type and
mutant strains; however, sit4Δ and kti12Δ mutants show
significantly more growth (𝑃 < 0.005) than the parental
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Figure 3: Response of sit4Δ and kti12Δ mutants to phytoceramide and long chain bases. Yeast cultures were diluted to 5 × 103 cells/mL in
YPD with the addition of the indicated concentrations of (a) phytoceramide, (b) dihydrosphingosine (DHS), (c) phytosphingosine (PHS),
or an equal volume of ethanol. Cells were grown until the untreated culture reached exponential phase and then the OD
600
of both treated
and untreated cells was measured and plotted as a percentage of untreated growth. Raw OD
600
values are given in Supplementary Table 2. A
minimum of three replicates are shown and error bars represent the standard error above and below the mean. A Student’s t-test was used to
determine if the mutants showed a significant difference in growth compared to the wild type (CY4029) at each concentration shown.
CY4029 strain at concentrations of 10–15𝜇M (Figure 3(a)).
In contrast, growth of sit4Δ and kti12Δ mutants in excess
dihydrosphingosine (DHS) is indistinguishable fromCY4029
(Figure 3(b)). The most striking result is that while kti12Δ
is also sensitive to phytosphingosine (PHS), sit4Δ shows
significant (𝑃 < 0.05) resistance to 3–6 𝜇MPHS (Figure 3(c)),
suggesting divergence of function between Kti12p and Sit4p
in the response to long chain bases.
3.4. Ceramide and Long Chain Base Levels Are Reduced
in sit4Δ and kti12Δ Mutants. To investigate the possibility
that Sit4p and Kti12p regulate the sphingolipid biosynthesis
pathway, we measured steady state levels of ceramides, long
chain bases, and inositol phosphate in sit4Δ and kti12Δ
strains relative to wild-type yeast cells. Deletion of SIT4 or
KTI12 reduces the intracellular levels of phytoceramide by
approximately 50% (Figure 4(a)). Levels of dihydroceramide
are also reduced in both mutants, but the decrease is only
statistically significant in sit4Δ (Figure 4(a)). This suggests
that the mutants may be able to tolerate otherwise toxic
levels of exogenous ceramides due to the constitutively
lower levels present within the cell. The reduction of PHS
levels by approximately two-thirds in the sit4Δmutant could
permit the strain to survive excess concentrations of PHS
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Figure 4: Mass spectrometric analysis of sphingolipid species. Yeast cultures were diluted to an OD
600
of 0.2 in YPD and grown for 8 hours
at 24∘C. A total of 10OD
600
units of cells were removed and lipids extracted for mass spectrometry analysis. (a) Ceramides, (b) long chain
bases phytosphingosine (PHS) and dihydrosphingosine (DHS), and (c) Inositol phosphoceramide-C (IPC-C) were quantified using relevant
internal standards. Average values for a minimum of three biological replicates are shown and error bars represent the standard error above
and below the mean. A Student’s t-test was used to determine if the mutants showed a significant difference from the wild type CY4029.
(∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.005).
(Figure 4(b)). However, a similar decrease in PHS levels
in the kti12Δ mutant does not correlate with resistance to
exogenous PHS (Figures 4(b) and 3(c)), suggesting that a
more complex mechanism underlies PHS resistance. There
is a small increase in the levels of DHS in sit4Δ and kti12Δ
mutants (Figure 4(b)) which is unlikely to affect the toxicity
of DHS seen in Figure 3(b).
3.5. Sit4 Mutants Show an Increase in the Proportion of
Dihydro Sphingolipids and a Corresponding Decrease in the
Proportion of Hydroxylated Sphingolipids. Tritium labelled
inositol incorporation was used to analyse the matura-
tion of complex sphingolipid species formed from both
dihydroceramide and phytoceramide. Dihydroceramide B󸀠
(18:0;2/26:0;0) and phytoceramide C (18:0;3/26:0;0) form
inositol phosphoceramide B (IPC-B) and inositol phosphoce-
ramide C (IPC-C) respectively. IPC-C and the corresponding
MIPC-C generated from it form the relativelymore abundant
species of their sphingolipid class in the wild type (Figure 5).
Interestingly, the sit4Δ mutant contains increased levels of
IPC-B and MIPC-B compared to the wild type, with a
decrease in the levels of IPC-C and MIPC-C (Figure 5). The
kti12Δmutant also shows a similar trend in the relative levels
of sphingolipid species, but the differences from the wild
type are less pronounced than those for sit4Δ. This indicates
a shift towards more sphingolipids being synthesised from
dihydroceramide/DHS precursors than from the hydroxy-
lated phytoceramide/PHS precursors. Figure 4(c) provides
additional evidence for this shift and quantification of IPC-
C levels shows a significant decrease in both sit4Δ and kti12Δ
mutants. This also correlates with the increase in DHS and
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Figure 5: Tritium labelled inositol incorporation into yeast cells.
CY4029 (WT), sit4Δ, and kti12Δ were incubated with [3H]-inositol
for 4 hours, and lipids were extracted and analysed by thin layer
chromatography, before and after mild-base treatment to remove
inositol phosphate (PI). Equal CPMswere loaded for all the samples.
A representative image of two biological replicates is shown.
decrease in PHS levels observed in sit4Δ and kti12Δmutants
(Figure 4(b)).
3.6. Novel Interactions of Sit4p with Tpd3p and Cdc55p
Suggest a Role for an Alternative Phosphatase Complex in
the Response to Ceramide. Previous studies suggested that
Tpd3p and Cdc55p could be part of the CAPP complex as
deletion of these genes conferred resistance to ceramide [10].
Indeed, we found via immunoprecipitation experiments with
HA-labelled Sit4p that Tpd3p and Cdc55p-c-myc interact
with Sit4p, forming a minor complex compared to the
Pph21p/Tpd3p/Cdc55p complex (Figure 6). As this novel
Sit4p/Tpd3p/Cdc55p trimer is formed constitutively and is
not induced by the presence of ceramide (data not shown),
the mechanism by which the phosphatase is activated in
response to an increase in ceramide levels remains unclear.
4. Discussion
The aim of this study was to further investigate the role of the
Sit4 phosphatase in response to ceramide and to determine if
this signalling pathway is directly related to the biosynthesis
of ceramides and sphingolipids. The phosphorylation status
of Orm1p regulates the activity of serine palmitoyltransferase
and therefore the production of all downstream products
of the sphingolipid pathway. Orm1p is phosphorylated by
Ypk1p and evidence suggests that dephosphorylation may
involve Sit4p and/or its TOR-dependent subunit Tap42p
[25, 26]. However, Orm1p is unlikely to be the direct sub-
strate for the Sit4p or Tap42p phosphatases as mutation of
these genes leads to decreased phosphorylation of Orm1p
[25].
The Sit4 phosphatase is a well-characterised regulator of
tRNAmodification via the Elongator complex [18, 21, 27–29].
However, here we show that the role of Sit4p in the ceramide
response is independent of Elongator yet still involves
the multifunctional and Elongator-related accessory protein
Kti12p. Although previous work suggested that Elongator
may be involved in ceramide resistance [18], more detailed
analysis in this current study indicates that Elongatormutants
are sensitive to ceramide. Although Kti12p is essential for
the phosphoregulation of Elongator, its precise role remains
unclear [18, 21]. Kti12p also has diverse roles in other cellular
processes including the cell cycle [30] and transcription [31],
and regulation of the ceramide response can now be added to
this list.
The Sit4 phosphatase has multiple regulatory subunits
including the Sit4 associated proteins (SAPs) Sap4p, Sap155p,
Sap185p, and Sap190p. A quadruple deletion of all SAPs is
sensitive to excess ceramide, in contrast to the resistant sit4Δ
mutant. Importantly, this is the first separation of function
observed between the sit4Δ and sapΔΔΔΔ mutants. This
suggests that an alternative Sit4 phosphatase complex is
involved in the regulation of the ceramide response, support-
ing the idea that this process is independent of Elongator
functions that require Sit4/Sap complexes. The identification
of a Sit4p/Tpd3p/Cdc55p trimer also supports the theory that
the ceramide activated protein phosphatase could be acting
via a previously unknown mechanism.
The alteration of the sphingolipid makeup in sit4Δ and
kti12Δ mutants and the decreased levels of ceramide and
long chain bases indicate that there is regulation of the
biosynthetic pathway at some level by Sit4p and/or Kti12p.
The decreased level of endogenous ceramide and PHS in the
mutants presumably enables them to survive an otherwise
toxic concentration of these compounds. This suggests that
deletion of SIT4 and KTI12 mediates a downregulation or
partial inactivation of ceramide synthesis rather than a
complete block, as there are clearly sufficient precursors
available for effective biosynthesis of sphingolipids.The pres-
ence of multiple genes encoding enzymes for synthesis and
degradation of ceramides is a key way in which sphingolipid
metabolism can be maintained when the pathway is partially
blocked. Phosphoregulation of ceramide synthases has not
been previously observed, but three phosphorylated serine
residues are conserved in both Lag1p and Lac1p ceramide
synthases and could be potential targets for dephosphory-
lation by Sit4p [32, 33]. In common with sit4Δ and kti12Δ
mutants, lac1Δlag1Δmutants are resistant to the tRNase toxin
zymocin, but the mechanism of action is due to a defect in
plasma membrane integrity caused by decreased levels of the
sphingolipid M(IP)
2
C and not via Elongator [34].
In sit4Δ and kti12Δ mutants, the relative proportion of
lipids synthesised from dihydroceramides/DHS is higher
than those synthesised from phytoceramides/PHS, suggest-
ing that there could be a defect in the Sur2 hydroxylase which
hydroxylates both long chain bases and ceramides [35]. This
is also reflected in the increased levels of DHS seen in the
mutants and is therefore unlikely to simply be a defect in the
synthesis of ceramide or downregulation at an earlier stage
in the pathway, as not all components of the pathway are
downregulated. The ceramidases Ypc1p and Ydc1p also have
a minor ceramide synthase activity and show specificity for
8 Oxidative Medicine and Cellular Longevity
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Figure 6: Immunoprecipitation of HA-Sit4p reveals novel interactors. Equal amounts of protein extracts were immunoprecipitated with
magnetic beads coated with anti-HA antibodies, and the precipitates were then subjected to Western blotting and probed with anti-HA and
anti-Tpd3 (a) or anti-c-myc (b) antibodies. Equal amounts of total protein extracts (without immunoprecipitation) were also probed with
anti-Tpd3 or anti-c-myc antibodies.
hydroxylated andnonhydroxylated forms of long chain bases,
respectively. [36] Dysregulation in sit4Δ could cause a shift
towards the synthesis of nonhydroxylated sphingolipids by
these enzymes. However, these enzymes contribute a minor
level of ceramide synthase activity compared to Lag1p, Lac1p,
and Lip1p [37], so a change in their regulation is unlikely
to have any detrimental effects on the overall sphingolipid
composition of the plasma membrane, even if the balance of
individual components is altered.
These new insights into the novel ceramide-associated
functions of Sit4p and Kti12p are helpful in understanding
the diverse roles these proteins play in the cell and expand
our knowledge of their importance beyond their association
with the Elongator complex. Relatively little is known about
the human orthologues of Sit4p and Kti12p, and thus yeast
studies are vital in unravelling the essential role they play in
regulating cell proliferation and cell death in both healthy and
malignant cells.
5. Conclusions
This study indicates that the roles of Sit4p and Kti12p in the
ceramide response are distinct from their roles in the regula-
tion of the Elongator complex and are therefore likely to be
mediated via a novel mechanism. The separation of function
between sit4Δ and sapΔΔΔΔ mutants and the interaction of
Sit4p with the alternative regulatory subunits Cdc55p and
Tpd3p also support this theory. Alterations in the levels of
ceramides, long chain bases, and complex sphingolipids in
sit4Δ and kti12Δ mutants indicate that these proteins are
also likely to regulate the sphingolipid biosynthesis pathway.
Future work will be targeted at delineating the underlying
mechanism(s) underlying these observations.
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